C3BS Raises €19 Million Through a Private Placement
News Jul 09, 2013
Cardio3 BioSciences (C3BS) has announced that it has increased its equity by €19 million through a private placement with existing investors.
The new funds will be used to finance the on-going clinical development of the Company’s lead product, C-Cure®, currently tested in Europe in a Phase III trial (CHART-1 - Congestive Heart failure Cardiopoietic Regenerative Therapy) and the preclinical development of other product candidates.
CHART-1 is the world’s first phase III trial using pre-programmed cardiac progenitor cells and targeting heart failure.
Of the €19 million raised, €7 million is in new equity committed by existing investors with €12 million resulting from the conversion of existing convertible loans.
The formal capital increase was approved at a shareholder meeting and is expected to complete by the end of May 2013.
C3BS’ C-Cure is a unique therapy that allows the reprogramming of bone marrow cells into ‘cardiopoïetic’ cells with the aim of growing new heart tissue thereby repairing damaged heart muscle.
The cardiopoietic cells are injected into the patient’s heart through a minimally invasive procedure using a proprietary catheter called C-Cath®ez.
C-Cure is the outcome of research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre Aalst (Aalst, Belgium).
Christian Homsy, CEO of Cardio3 BioSciences commenting on today’s announcement said, “Our ability to raise this significant amount of funding demonstrates the commitment of our investors and their confidence in the considerable value that we can generate from C-Cure. The new funding will allow us to proceed with our European Phase III trial in patients with Congestive Heart failure. We are confident that this study will confirm that C-Cure has the potential to significantly improve the disease course of those very sick patients, and could lead to a paradigm shift in the treatment of heart failure.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE